Panobinostat potentiates the cytotoxic effects of ara-C and daunorubicin on acute myeloid leukemia cells through suppressing the DNA damage response

被引：0

作者：

Xie, Chengzhi ^{[1
]}

Edwards, Holly ^{[1
]}

Drenberg, Christina ^{[2
]}

Baker, Sharyn D. ^{[2
]}

Inaba, Hiroto ^{[2
]}

Buck, Steven A. ^{[3
]}

Taub, Jeffrey W. ^{[3
]}

Ge, Yubin ^{[1
]}

机构：

[1] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[2] St Jude Childrens Res Hosp, Memphis, TN 38105 USA

[3] Childrens Hosp Michigan, Detroit, MI 48201 USA

来源：

CANCER RESEARCH | 2012年 / 72卷

关键词：

D O I：

10.1158/1538-7445.AM2012-2739

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2739

引用

页数：2

共 50 条

[31] A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia [J].

A K Burnett ;

N H Russell ;

R K Hills ;

J Kell ;

O J Nielsen ;

M Dennis ;

P Cahalin ;

C Pocock ;

S Ali ;

S Burns ;

S Freeman ;

D Milligan ;

R E Clark .

Leukemia, 2017, 31 :310-317

[32] A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia [J].

Burnett, A. K. ;

Russell, N. H. ;

Hills, R. K. ;

Kell, J. ;

Nielsen, O. J. ;

Dennis, M. ;

Cahalin, P. ;

Pocock, C. ;

Ali, S. ;

Burns, S. ;

Freeman, S. ;

Milligan, D. ;

Clark, R. E. .

LEUKEMIA, 2017, 31 (02) :310-317

[33] Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients [J].

Dennis, Mike ;

Thomas, Ian F. ;

Ariti, Cono ;

Upton, Laura ;

Burnett, Alan K. ;

Gilkes, Amanda ;

Radia, Rohini ;

Hemmaway, Claire ;

Mehta, Priyanka ;

Knapper, Steven ;

Clark, Richard E. ;

Copland, Mhairi ;

Russell, Nigel ;

Hills, Robert K. .

BLOOD ADVANCES, 2021, 5 (24) :5621-5625

[34] CMA 676 in combination with ARA-C and liposomal daunorubicin high risk acute myelogenous leukemia patients. [J].

Günzelmann, S ;

Fauser, AA ;

Koldehoff, M ;

Basara, N ;

Kiehl, MG .

BLOOD, 2001, 98 (11) :257B-257B

[35] ENZYMATIC DETERMINANTS OF RESPONSE TO CYTOSINE-ARABINOSIDE (ARA-C) IN PATIENTS (PTS) WITH ACUTE MYELOID-LEUKEMIA (AML) [J].

RIVA, CM ;

DESOUZA, G ;

FERRIER, F ;

MERLIN, M ;

TUBIANA, N ;

LEJEUNE, C ;

GASTAUT, JA ;

BARRA, Y ;

CANO, JP ;

CARCASSONNE, Y .

PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 :502-502

[36] Combination therapy with aclarubicine, etoposide and Ara-c (AVA) in the treatment of acute myeloid leukemia in the elderly [J].

Staib, P ;

Lathan, B ;

Steinmetz, HT ;

Schwonzen, M ;

KnoppelSchwark, S ;

Wickramanayke, PD ;

Tesch, H ;

Diehl, V .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 :852-852

[37] ARA-C, IDARUBICINE AND GEMTUZUMAB OZOGAMICIN AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS [J].

Capria, S. ;

Cardarelli, L. ;

Trisolini, S. M. ;

Cartoni, C. ;

Minotti, C. ;

Gianfelici, V ;

Arleo, E. ;

Santini, L. ;

De Propris, M. S. ;

Mancini, M. ;

Martinelli, G. ;

Foa, R. ;

Meloni, G. .

HAEMATOLOGICA, 2008, 93 :S84-S84

[38] Irinotecan (CPT-11) and cytarabine (Ara-C) in refractory acute myeloid leukemia (AML). [J].

Minderman, H ;

O'Loughlin, KL ;

Thomas, KJ ;

Pixley, LA ;

Wetzler, M ;

Slack, JL ;

Baer, MR .

LEUKEMIA, 2001, 15 (03) :509-509

[39] Safety and efficacy of different Ara-C regimens during the clinical course of acute myeloid leukemia [J].

Ciftciler, R. ;

Haziyev, T. ;

Aladag, E. ;

Buyukasik, Y. ;

Haznedaroglu, I. ;

Goker, H. ;

Demiroglu, H. .

LEUKEMIA RESEARCH, 2018, 73 :S35-S36

[40] SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA [J].

Malato, A. ;

Santoro, A. ;

Felice, R. ;

Magrin, S. ;

Turri, D. ;

Di Bella, R. ;

Salemi, D. ;

Acquaviva, F. ;

Scime, R. ;

Fabbiano, F. .

HAEMATOLOGICA, 2013, 98 :31-31

← 1 2 3 4 5 →